The patent application, titled ‘Pharmaceutical Composition with Ionically Crosslinked Polymer Encapsulation of Active Ingredient’ (US-2017-0100327), covers the proprietary matrix, encapsulation technologies and the manufacturing process for the California, US-headquartered company’s oral film delivery platform, CureFilm.
The firm will target “companies that need to have a better delivery vehicle for their proprietary APIs,” with its platform in order to deliver medicines for orphan, geriatric and paediatric diseases, a spokesperson told in-PharmaTechnologist.
API-loaded film tech
CureFilm is created by integrating encapsulated active ingredients in a web formed by a blend of polymers, and other agents with properties providing permeation enhancement.
The film has taste-masking and musco-adhesive qualities.
“CureFilm is a unique delivery matrix that allows for delivery of APIs in several drug delivery routes such as through the buccal, upper GI, lower GI or a combination of all three,” a spokesperson told us.
“There are a plethora of molecules that can be applied to CureFilm, limitations are based on molecule size and dosing amount, although Cure can deliver higher amounts of active than any other oral thin film company in the market,” the spokesperson said.
In addition, it has high bioavailability, and can be easily administered regardless of state of consciousness, which can be valuable to emergency medicine, said the spokesperson.
CureFilm can benefit older and younger generations, the spokesperson explained: “Geriatric patient population and paediatric population have a high incidence of dysphagia and trouble swallowing pills.”
Further, water is not required in the administering of CureFilm, and it is highly portable and lightweight, which can be an advantage for logistics, we were told.
Patent and licensing plans
Cure Pharma aims to license the use of its technology to deliver proprietary molecules and APIs, while maintaining full control over all manufacturing processes.
Due to CureFilm’s sustainable and scalable process, the product to the patient price point is comparable to other delivery modes, the spokesperson told us.
“This publication by the USPTO [US Patent and Trademark Office] of our Crosslink patent is an important step in the application process, moving us closer to our goal of approval and issuance of this patent,” said CEO Rob Davidson.